Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607666 | 0.85 | — | — | |
| SCHEMBL17607465 | 0.81 | LMNA (0.33) | LMNA | |
| SCHEMBL17607442 | 0.77 | METAP1 (0.33) | — | |
| SCHEMBL3028361 | 0.76 | LMNA (0.40) | LMNA | |
| SCHEMBL598055 | 0.76 | LMNA (0.40) | LMNA | |
| SCHEMBL1404786 | 0.76 | LMNA (0.48) | LMNA | |
| SCHEMBL10958918 | 0.75 | LMNA (0.36) | LMNA | |
| SCHEMBL11223706 | 0.75 | TSHR (0.31) | — | |
| SCHEMBL60773 | 0.74 | — | — | |
| SCHEMBL2338438 | 0.73 | LMNA (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777776-B | Inhibitors of protein tyrosine kinase activity | 梅特希尔基因公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-107438435-B | anti-HCMV compositions and methods | 埃弗里斯生物有限责任公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190256509-A1 | HISTONE DEMETHYLASE INHIBITORS | CHRYSALIS INC (US) | 2019-08-22 | — | — | US | disclosed |
| CN-109970759-A | The inhibitor of protein tyrosine kinase activity | 梅特希尔基因公司 | 2019-07-05 | — | — | CN | disclosed |
| US-20190055212-A1 | HISTONE DEMETHYLASE INHIBITORS | GWALTNEY STEPHEN (US) | 2019-02-21 | — | — | US | disclosed |
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017143011-A1 | HISTONE DEMETHYLASE INHIBITORS | Chrysalis, Inc. (US) | 2017-08-24 | — | — | WO | disclosed |
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
| CN-1723207-A | Histone deacetylase inhibitors | METHYLGENE INC (CA) | 2006-01-18 | — | — | CN | disclosed |
| CN-1705635-A | Inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2005-12-07 | — | — | CN | disclosed |
| EP-1597255-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Rigel Pharmaceuticals, Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| CN-1578663-A | Histone deacetylase inhibitors | METHYLGENE INC (CA) | 2005-02-09 | — | — | CN | disclosed |
| WO-2004043955-A1 | RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RIGEL PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | LMNA 851/4885 |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | LMNA 4411/4885 |
| US-20190256509-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6B, KDM2A | LMNA 2465/4885 |
| US-20190055212-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6B, KDM5B | LMNA 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.